News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Carmenta Bioscience Secures Over $2 Million in Oversubscribed Seed Financing



8/7/2013 9:55:22 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PALO ALTO, Calif.--(BUSINESS WIRE)--Carmenta Bioscience, Inc., a privately held medical technology company focused on maternal and fetal health, today announced it has secured over $2M in seed funding. Proceeds from the financing will support development and commercialization of a new, proprietary test to better diagnose and predict preeclampsia in pregnant women. The test is based on a worldwide, exclusive technology license from Stanford University. Arising in 5-8% of pregnant mothers, preeclampsia is a leading cause of both preterm birth and maternal and fetal death.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES